## **AMENDMENTS TO THE CLAIMS**

Please amend the claims as follows:

Please cancel claims 3 and 11-16.

1. (Currently amended) An opener or activator compound which modulates the biological activity of central nervous system-associated KCNQ potassium channel polypeptides by hyperpolarizing neurons that fire before or during a migraine headache or migraine-related disorder, the opener or activator compound comprising a compound according to Formula I and pharmaceutically acceptable salts thereof, Formula I having the structure

$$R^2$$
 $R^3$ 
 $R^4$ 
 $R^5$ 
 $R^6$ 
 $R^7$ 

wherein

 $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are each independently hydrogen,  $C_{1.4}$  alkyl halogen, fluoromethyl, trifluoromethyl, phenyl, 4-methylphenyl or 4-trifluromethylphenyl;

 $R^5$  is  $C_{1-6}$  alkyl, optionally substituted with one to three same or different groups selected from fluoro and chloro, provided that  $R^5$  is not  $C_{1-6}$  alkyl when Y is O;

Y is O or S; and

R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen, chloro, bromo or trifluoromethyl.

2. (Currently amended) An opener or activator compound which modulates the biological activity of central nervous system-associated KCNQ potassium channel polypeptides by preventing abnormal synchronous neuronal firing associated with migraine or migraine-related disorders, the opener or activator compound comprising a compound according to Formula I and pharmaceutically acceptable salts thereof, Formula I having the structure

$$R^2$$
 $R^3$ 
 $R^4$ 
 $R^5$ 
 $R^6$ 
 $R^7$ 

wherein

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, C<sub>1-4</sub> alkyl halogen, fluoromethyl, trifluoromethyl, phenyl, 4-methylphenyl or 4-trifluromethylphenyl;

 $R^5$  is  $C_{1-6}$  alkyl, optionally substituted with one to three same or different groups selected from fluoro and chloro, provided that  $R^5$  is not  $C_{1-6}$  alkyl when Y is O;

Y is O or S; and

R<sup>6</sup> and R<sup>7</sup> are each independently hydrogen, chloro, bromo or trifluoromethyl...

## 3. (Canceled)

4. (Currently amended) The compound according to claim 1/2, wherein the opener or activator compound is (+)-3-[5-Chloro-2-[(2,2,2-trifluoroethoxy)phenyl]-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one or -2-(Pyrrolidin 1-yl) 4 (trifluoromethyl) N [[4 (trifluoromethyl) phenyl]methyl] pyrimidine 5-carboxamide.

- 5. (Original) The compound according to claim 1 or claim 2, wherein the KCNQ potassium channel polypeptide is selected from the group consisting of one or more of KCNQ2, KCNQ3, KCNQ4, KCNQ5, and heteromultimers thereof.
- 6. (Original) A method of modulating neuronal activity associated with migraine or a migraine-related disorder, comprising administering to an individual in need thereof an amount of the compound according to claim 1 or claim 2 effective to inhibit neuronal activity, thereby reducing, ameliorating or alleviating migraine or a migraine-related disorder.
- 7. (Original) The method according to claim 6, wherein said neuronal activity is selectively inhibited with the trigeminovascular system of the central nervous system.
- 8. (Original) A method of treating migraine or migraine-related disorder, comprising: administering to an individual in need thereof an opener of a CNS-located KCNQ potassium channel protein, or functional portion thereof, according to claim 1 or claim 2, in an amount effective to selectively limit neuronal hyperexcitability during a migraine attack or migraine-related disorder by opening the CNS-located KCNQ potassium channel protein so as to protect against abnormal synchronous firing of neurons.
- 9. (Original) The method according to claim 8, wherein the neuronal hyperexcitability occurs within the trigeminovascular system of the central nervous system.
- 10. (Original) The method according to claim 6 or claim 8, wherein the KCNQ potassium channel protein is selected from the group consisting of KCNQ2, KCNQ3, KCNQ4, KCNQ5 and heteromultimers thereof.

## 11-16. (Canceled)

17. (New) The compound according to claim 2, wherein the opener or activator compound is (+)-3-[5-Chloro-2-[(2,2,2-trifluoroethoxy)phenyl]-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2*H*-indol-2-one.